ZNTL Zentalis Pharmaceuticals, Inc. Insider Trading

10% Owner WALTERS GROUP buys 6,459,973 shares of ZNTL at $1.20 ($7.8M), increasing stake to 13,509,973 shares (+91.6%)

WALTERS GROUP, a 10% shareholder, executed a substantial 6,459,973-share purchase at $1.20 per share, increasing aggregate holdings by 91.6% to 13,509,973 shares post-transaction. The acquisition occurred when the current stock price is $2.84—137% higher than the transaction price—and represents 30-day momentum of +105.8% and 90-day appreciation of +69.0%. Zentalis is unprofitable with $-26,691,000 net income and zero revenue in the latest quarter, placing this accumulation within a context of significant operational losses. The timing and scale of this stake increase—doubling down from 7.05M to 13.51M shares—merits examination of whether the insider expects a meaningful inflection in the underlying business or is responding to specific development milestones not yet visible in quarterly results.

10% owner Matrix Capital sold 7,500,000 shares of ZNTL at $1.33; stock down 61.2% from 52-week high of $3.61

Matrix Capital Management Company, LP divested 7,500,000 shares (53.7% of pre-transaction holdings) at $1.33, reducing its stake from 13,959,973 to 6,459,973 shares. The sale price sits well below the 52-week high of $3.61, and the current price of $1.40 reflects a steep decline across the stock. Zentalis operates with zero revenue and $-26,691,000 net income in its latest quarter, indicating a pre-revenue biotech facing significant cash burn. The 10% insider's substantial divestiture at a depressed valuation window—combined with the company's unprofitable status and negative trailing performance—reflects a material shift in the major shareholder's commitment to the position.

Director Myers Scott Dunseth buys 21,000 ZNTL shares at $1.40; stock down 88.7% from 52-week high, company posted $-40.2M loss

Director Myers Scott Dunseth purchased 21,000 shares of Zentalis Pharmaceuticals at $1.40 on 2025-04-30, increasing his holdings to 281,192 shares, during a period when the stock trades at $1.42 and has declined 88.7% from its 52-week high of $12.54. The company is unprofitable with a $-40,158,000 net loss in its most recent fiscal year and zero revenue in the latest quarter, indicating an early-stage biotech profile with significant operational losses. Dunseth's historical cross-ticker buy performance shows an average 90-day return of -19.2% with a 0.00% win rate, establishing a pattern of unfavorable subsequent price action following his purchases. This buy occurs while the stock is already significantly depressed in price; investors should monitor whether this transaction reflects access to non-public information regarding clinical progress or financing, or whether it represents a continuation of Dunseth's historical pattern of purchases preceding further declines.

CMO Bruns Ingmar bought 20,000 shares of ZNTL at $2.28; stock now $2.16, down 86.6% from 52-week high

Chief Medical Officer Bruns Ingmar purchased 20,000 shares at $2.28 on 2025-02-06, more than doubling his post-transaction holdings to 36,629 shares from 16,629 shares. The stock is trading at a steep discount to its 52-week high of $16.13, currently down 86.6% from that peak and off 15.6% over the past 30 days. The company generated no revenue in its latest quarter and reported a net loss of $40,158,000.00, with unprofitability across its most recent full fiscal year. Notably, this purchase is part of a cluster pattern with 3 other insiders also buying within the past 14 days, suggesting coordinated action by company leadership during a period of severe stock decline and operational losses.

Director Walker bought 14.2K shares at $1.76 (now $1.63, -49.7% in 30d); cluster buy pattern with 2 insiders in 14 days; unprofitable company.

Walker Luke Nathaniel acquired 14,200 shares at $1.76 on 2025-01-31, raising his holdings to 86,681 shares, a 19.6% increase from prior holdings of 72,481 shares. This purchase occurred in a cluster pattern where 2 other insiders also bought within the past 14 days, suggesting coordinated management interest despite the company's deteriorating valuation. However, the macroscopic context is challenging: the stock is trading at $1.63, down 49.7% in the past 30 days and 57.6% in 90 days—now 89.9% below its 52-week high of $16.13. Zentalis is unprofitable with quarterly revenue of $0.00 and a net loss of $40.2M over the most recent full fiscal year, creating significant execution risk. The simultaneous cluster activity and steep valuation collapse merit investigation into whether insiders are positioned for stabilization or whether the buy pattern reflects access to material information not yet public.

CEO Julia Marie Eastland buys 28,500 shares at $1.73 amid cluster buy; stock down -89.9% from 52-week high.

CEO Julia Marie Eastland purchased 28,500 shares at $1.73 on 2025-01-31 while the stock trades at $1.63 current price, representing a -89.9% decline from the 52-week high of $16.13. This transaction occurred as part of a cluster buy pattern, with 2 other insiders also purchasing within the past 14 days. The company's fundamentals show acute distress: Revenue of $0.00 in the latest quarter and a net loss of $-40,158,000.00 over the most recent full fiscal year, reflecting a pre-revenue biotech model with substantial cash burn. The CEO's acquisition of an initial position (0 to 28,500 shares) coinciding with coordinated insider buying at deeply depressed valuations merits scrutiny as a factual matter, particularly given the magnitude of the stock decline and the company's loss profile.

Director Skvarka buys 60,000 ZNTL shares at $1.72 amid cluster buy; stock -89.9% from 52-week high.

Director Jan Skvarka purchased 60,000 shares at $1.72 on 2025-01-31, expanding his holdings by 67.0% to 149,551 shares. This transaction is part of a cluster buy pattern, with 2 other insiders also purchasing within the past 14 days, suggesting aligned interest at the company level rather than isolated conviction. The context is stark: the stock trades at $1.63 (current price), down -89.9% from its 52-week high of $16.13, while the company reported zero quarterly revenue and a net loss of $-40,158,000.00 in its most recent period. This acquisition by a director during severe price depression and ongoing unprofitability warrants examination of whether board-level visibility into operational trajectory or financing initiatives informed the timing, though such visibility cannot be inferred from the transaction alone.